DBT–BIRAC Host 12th Webinar on Cell & Gene Therapy Advancements

21 Apr 2025 CW Team

With its transformative potential in treating complex and previously incurable diseases, Cell and Gene Therapy (CGT) is a priority area within the BioE3 vision to position India as a global leader in sustainable, high-performance biomanufacturing.

Highlights from the Webinar Dr Alka Sharma, Senior Adviser, DBT, opened the session by reiterating the BioE3 Policy’s mission to support green, high-impact biomanufacturing. She emphasised the need for strategic interventions to overcome sectoral challenges and drive growth in CGT innovation and accessibility.

Dr Kamakshi Chaithri, Scientist ‘D’, DBT, stressed the urgent need to prioritise this domain, particularly for life-threatening conditions like cancer and rare diseases. She outlined global and national positioning and underlined the DBT’s ongoing efforts to build a conducive innovation ecosystem for indigenous CGT development.

Dr Debojyoti Chakraborty, Principal Scientist at CSIR–IGIB, discussed cutting-edge gene editing technologies targeting sickle cell anaemia, ocular disorders, and more. He noted the regulatory and manufacturing bottlenecks and the importance of ensuring therapies are affordable and accessible.

Dr Anil Kamat, Head of Clinical Development, Immuneel Therapeutics, spoke on the commercial approval of CAR-T Cell therapy, supported by BIRAC. He discussed scale-up challenges and suggested solutions for improving access, affordability, and availability of CGTs.

The Department of Biotechnology (DBT), Government of India, in collaboration with BIRAC, held the 12th webinar under its Biomanufacturing and Biofoundry Initiative on 17th April 2025. Themed around “Cell and Gene Therapy”, the session falls under the Precision Biotherapeutics focus of the BioE3 (Biotechnology for Economy, Environment & Employment) Policy, which was approved by the Union Cabinet in August 2024. With its transformative potential in treating complex and previously incurable diseases, Cell and Gene Therapy (CGT) is a priority area within the BioE3 vision to position India as a global leader in sustainable, high-performance biomanufacturing. Highlights from the Webinar Dr Alka Sharma, Senior Adviser, DBT, opened the session by reiterating the BioE3 Policy’s mission to support green, high-impact biomanufacturing. She emphasised the need for strategic interventions to overcome sectoral challenges and drive growth in CGT innovation and accessibility. Dr Kamakshi Chaithri, Scientist ‘D’, DBT, stressed the urgent need to prioritise this domain, particularly for life-threatening conditions like cancer and rare diseases. She outlined global and national positioning and underlined the DBT’s ongoing efforts to build a conducive innovation ecosystem for indigenous CGT development. Dr Debojyoti Chakraborty, Principal Scientist at CSIR–IGIB, discussed cutting-edge gene editing technologies targeting sickle cell anaemia, ocular disorders, and more. He noted the regulatory and manufacturing bottlenecks and the importance of ensuring therapies are affordable and accessible. Dr Anil Kamat, Head of Clinical Development, Immuneel Therapeutics, spoke on the commercial approval of CAR-T Cell therapy, supported by BIRAC. He discussed scale-up challenges and suggested solutions for improving access, affordability, and availability of CGTs.

Infrastructure Transport

07 Aug 2026

Government Plans Rs 450 bn Rail Investment Along Borders

The government plans to invest Rs 450 bn to upgrade railways along borders with China, Pakistan and Bangladesh, the press release said. The programme will run over 18 to 24 months and will finance new tracks, platforms and network strengthening across Punjab, West Bengal, Himachal Pradesh, Rajasthan, Assam and several northeastern states. That is about $4.7 bn. Officials indicated the initiative represents nearly 22 per cent of all railway infrastructure outlay planned over the next two years and is among the most significant strategic infrastructure pushes in recent years. The plan extends be..

Infrastructure Transport

07 Aug 2026

Indian Railways Approves Daily Express Between Mumbai CSMT And Sawantwadi Road

Indian Railways has approved a new daily express service between Chhatrapati Shivaji Maharaj Terminus (CSMT), Mumbai, and Sawantwadi Road to boost rail connectivity across Maharashtra and the Konkan region. The service will operate over a 510-km route and will run daily as Train No. 15087 CSMT–Sawantwadi Road Express and Train No. 15088 Sawantwadi Road–CSMT Express. It is intended to provide direct and reliable rail connectivity for passengers travelling for tourism, education, employment and business. The Ministry of Railways said the move forms part of ongoing efforts to expand passenger..

Infrastructure Urban

07 Aug 2026

SECR Invites Rs 4550.2 mn EPC Tender For Chhattisgarh Line

South East Central Railway (SECR) has invited bids for an engineering, procurement and construction (EPC) contract worth Rs 4550.2 mn for a section of the Dallirajhara-Rowghat-Jagdalpur New Railway Line in Chhattisgarh. The contract covers a nearly 30 km stretch between Kurkanar and Bhanpuri and forms part of the larger corridor linking the mineral-rich Bastar region with the state rail network. The authority has positioned the package as a key link to improve passenger and freight movement within the region. Tender documents carry tender number CAO-C-BSP-26-27-14 and an earnest money deposit ..